Clinical Trials May Not Benefit Cancer Patients

Susan Farley
Published Online: Thursday, April 1, 2004

According to the results of a recent study, published in the Lancet, cancer patients who participate in clinical trials are no better or worse off than patients who do not participate in trials. A common misperception is that cancer patients who get into clinical trials for new drug therapies and treatments have a better chance of recovery than those who do not. The researchers believe that this supposed benefit may be because these patients are more closely monitored or that their doctors adhere more rigorously to standard treatment plans. Steven Joffe, MD, of the Dana-Farber Cancer Institute in Boston, Mass, and his colleagues reviewed 26 published studies comparing outcomes of cancer patients in trials and outcomes of patients not in trials. Fourteen of the studies suggested more favorable outcomes for patients in studies, but the authors maintain that these studies did not control well for bias. Dr. Joffe said, "You don't know if the differences reflect the treatment or the fact that they were different to start with. Maybe [the patients] are going to a better treatment center, so the message is not necessarily, get yourself into a trial, but go to a good treatment center."\

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues